Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 732

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 732
---
 risk) and presents the revenue earned each period as collaborative revenue.

For the three months ended September 30, 2024, CSL Vifor recorded net sales of KORSUVA injection in the United States of approximately$ 3,004, which resulted in the Company’s profit share amount of$ 1,298. For the three months ended September 30, 2023, CSL Vifor recorded net sales of approximately$ 4,400, which resulted in the Company’s profit share amount of$ 1,932. For the nine months ended September 30, 2024, CSL Vifor recorded net sales of KORSUVA injection in the United States of approximately$ 2,146, which included negative net sales reported by CSL Vifor for the second quarter of 2024 primarily due to higher rebates and chargebacks due to price decreases on KORSUVA injection related to the expiration of Transition Drug Add-on Payment Adjustment in April 2024. For the nine months ended September 30, 2023, CSL Vifor recorded net sales of KORSUVA injection in the United States of approximately$ 21,500. For the nine months ended September 30, 2024 and 2023, the Company recorded associated collaborative revenue of$ 2,086and$ 10,092, respectively. However, the Company has recorded an expense in other general and administrative, or G&A, expense for$ 1,447for the nine months ended September 30, 2024 as a result of the negative profit share amount in the second quarter of 2024.

F- 21

<div align='center'>CARA THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share data)

(unaudited)</div>

The Company’s distinct performance obligations under the Maruishi Agreement include transfer of the license to the Company’s intellectual property, which allowed Maruishi to develop and commercialize difelikefalin, for acute pain and uremic pruritus indications in Japan, which occurred at inception of the contract in 2013 (considered license and milestone fees revenue), and performance of R&D services, which occurred from 2013 to 2015 (considered collaborative revenue), as those services were rendered. The Company agreed to conduct limited work on an oral tablet formulation of difelikefalin and to conduct Phase 1